<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>Peptide Press — Briefing</title><description>Exploring the science shaping the future of human biology — peptides, longevity, performance, and human potential.</description><link>https://peptide.press/</link><language>en-us</language><item><title>FDA advisers back six peptides for pharmacy compounding</title><link>https://peptide.press/articles/pcac-july-2026-peptide-compounding-vote/</link><guid isPermaLink="true">https://peptide.press/articles/pcac-july-2026-peptide-compounding-vote/</guid><description>In a divided two-day meeting, the Pharmacy Compounding Advisory Committee supported BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon, while rejecting Emideltide. The votes do not approve the peptides or immediately authorize their use in patient-specific pharmacy compounding.</description><pubDate>Sat, 25 Jul 2026 00:00:00 GMT</pubDate><category>research</category><category>FDA</category><category>Regulation</category><category>Compounding</category><category>BPC-157</category><category>Peptides</category></item><item><title>How the community is researching BPC-157</title><link>https://peptide.press/articles/how-the-community-researches-bpc-157/</link><guid isPermaLink="true">https://peptide.press/articles/how-the-community-researches-bpc-157/</guid><description>Oral versus injectable, local versus systemic, short cycle versus long — BPC-157 has some of the most elaborate community conventions of any peptide, built almost entirely on animal data and repetition rather than human trials.</description><pubDate>Sat, 18 Jul 2026 00:00:00 GMT</pubDate><category>peptides</category><category>BPC-157</category><category>Community Practice</category><category>Recovery</category><category>Regulation</category><category>FDA</category></item><item><title>How the community is researching CJC-1295 and ipamorelin</title><link>https://peptide.press/articles/how-the-community-researches-cjc-1295-ipamorelin/</link><guid isPermaLink="true">https://peptide.press/articles/how-the-community-researches-cjc-1295-ipamorelin/</guid><description>The peptide world&apos;s most familiar growth-hormone pairing runs on a specific logic: two receptors, complementary signaling, and a nightly ritual built largely outside controlled trials.</description><pubDate>Sat, 18 Jul 2026 00:00:00 GMT</pubDate><category>performance</category><category>CJC-1295</category><category>Ipamorelin</category><category>Community Practice</category><category>Growth Hormone</category><category>Regulation</category></item><item><title>How the community is researching MOTS-c</title><link>https://peptide.press/articles/how-the-community-researches-mots-c/</link><guid isPermaLink="true">https://peptide.press/articles/how-the-community-researches-mots-c/</guid><description>Intermittent schedules, exercise timing, and the mixture of animal research, mechanistic reasoning, and repetition that shaped today&apos;s community conventions.</description><pubDate>Sat, 18 Jul 2026 00:00:00 GMT</pubDate><category>longevity</category><category>MOTS-c</category><category>Community Practice</category><category>Mitochondria</category><category>Regulation</category><category>Metabolism</category></item><item><title>How the community is researching SS-31</title><link>https://peptide.press/articles/how-the-community-researches-ss-31/</link><guid isPermaLink="true">https://peptide.press/articles/how-the-community-researches-ss-31/</guid><description>Elamipretide is now an approved drug for one rare disease at a specific dose — yet the longevity community researches it at very different, usually lower amounts. The gap between the label and the practice is the story.</description><pubDate>Sat, 18 Jul 2026 00:00:00 GMT</pubDate><category>longevity</category><category>SS-31</category><category>Elamipretide</category><category>Community Practice</category><category>Mitochondria</category><category>Regulation</category></item><item><title>How the community is researching tesamorelin</title><link>https://peptide.press/articles/how-the-community-researches-tesamorelin/</link><guid isPermaLink="true">https://peptide.press/articles/how-the-community-researches-tesamorelin/</guid><description>Tesamorelin is unusual: an FDA-approved drug with a defined regimen and real trial data, used by the community for a different, off-label goal. Comparing the label with the practice is where this one gets interesting.</description><pubDate>Sat, 18 Jul 2026 00:00:00 GMT</pubDate><category>performance</category><category>Tesamorelin</category><category>Community Practice</category><category>Growth Hormone</category><category>Body Composition</category><category>Regulation</category></item><item><title>Three paths to mitochondrial resilience</title><link>https://peptide.press/articles/three-paths-to-mitochondrial-resilience/</link><guid isPermaLink="true">https://peptide.press/articles/three-paths-to-mitochondrial-resilience/</guid><description>If mitochondrial decline sits near the center of aging, the interesting question is how researchers are trying to address it. The research splits into three distinct strategies — protect the structure, restore the metabolic inputs, and strengthen the signals — and seeing them together is the best map of the field.</description><pubDate>Sat, 18 Jul 2026 00:00:00 GMT</pubDate><category>longevity</category><category>Mitochondria</category><category>Longevity</category><category>Healthspan</category><category>Aging</category><category>Exercise</category></item><item><title>MOTS-c vs SS-31: two very different ways to help a mitochondrion</title><link>https://peptide.press/articles/mots-c-vs-ss-31-two-strategies/</link><guid isPermaLink="true">https://peptide.press/articles/mots-c-vs-ss-31-two-strategies/</guid><description>They are both mitochondrial peptides, and they are almost opposites — one a natural signal that tells cells to adapt, the other a synthetic molecule that physically stabilizes the membrane. Comparing them is the clearest way to see how many angles mitochondrial medicine really has.</description><pubDate>Fri, 17 Jul 2026 00:00:00 GMT</pubDate><category>longevity</category><category>MOTS-c</category><category>SS-31</category><category>Mitochondria</category><category>Comparison</category><category>Longevity</category></item><item><title>NAD+ and the aging cell: the molecule everything runs on</title><link>https://peptide.press/articles/nad-and-the-aging-cell/</link><guid isPermaLink="true">https://peptide.press/articles/nad-and-the-aging-cell/</guid><description>NAD+ sits at the center of how cells make energy and repair themselves, and it appears to fall with age. That has made raising it one of the most pursued ideas in longevity — and one of the most instructive tests of how biology translates from mice to people.</description><pubDate>Thu, 16 Jul 2026 00:00:00 GMT</pubDate><category>longevity</category><category>NAD+</category><category>NMN</category><category>Nicotinamide Riboside</category><category>Metabolism</category><category>Aging</category><category>Clinical Trials</category></item><item><title>SS-31 (elamipretide): a peptide designed to protect the mitochondrial membrane</title><link>https://peptide.press/articles/ss-31-elamipretide-cardiolipin/</link><guid isPermaLink="true">https://peptide.press/articles/ss-31-elamipretide-cardiolipin/</guid><description>Most mitochondrial strategies work on signaling or fuel. SS-31 does something more structural — it binds the lipid that holds the energy machinery together. In 2025 it became the first mitochondria-targeted drug the FDA has ever approved.</description><pubDate>Wed, 15 Jul 2026 00:00:00 GMT</pubDate><category>longevity</category><category>SS-31</category><category>Elamipretide</category><category>Cardiolipin</category><category>Mitochondria</category><category>Clinical Trials</category></item><item><title>Retatrutide: why a triple receptor agonist is drawing so much attention</title><link>https://peptide.press/articles/retatrutide-triple-agonist/</link><guid isPermaLink="true">https://peptide.press/articles/retatrutide-triple-agonist/</guid><description>By engaging three metabolic receptors at once — GLP-1, GIP, and glucagon — retatrutide represents a genuinely new idea in metabolic pharmacology. Here is what triple agonism means, and what the human data shows so far.</description><pubDate>Mon, 13 Jul 2026 00:00:00 GMT</pubDate><category>peptides</category><category>Retatrutide</category><category>GLP-1</category><category>GIP</category><category>Glucagon</category><category>Clinical Trials</category><category>Metabolism</category></item><item><title>Why mitochondrial decline matters in aging</title><link>https://peptide.press/articles/why-mitochondrial-decline-matters-in-aging/</link><guid isPermaLink="true">https://peptide.press/articles/why-mitochondrial-decline-matters-in-aging/</guid><description>Mitochondria do far more than make energy — and their gradual dysfunction sits close to the center of why bodies age. A guide to the biology that has made mitochondria one of the most important targets in longevity research.</description><pubDate>Mon, 13 Jul 2026 00:00:00 GMT</pubDate><category>longevity</category><category>Mitochondria</category><category>Aging</category><category>Healthspan</category><category>Mitophagy</category><category>Metabolism</category></item><item><title>Growth hormone secretagogues explained: how ipamorelin, CJC-1295, and related compounds differ</title><link>https://peptide.press/articles/growth-hormone-secretagogues-explained/</link><guid isPermaLink="true">https://peptide.press/articles/growth-hormone-secretagogues-explained/</guid><description>They are often mentioned in one breath, but the peptides that raise growth hormone work through genuinely different mechanisms — and the differences matter. A guide to the growth hormone axis and the molecules that act on it.</description><pubDate>Sun, 12 Jul 2026 00:00:00 GMT</pubDate><category>performance</category><category>Ipamorelin</category><category>CJC-1295</category><category>Growth Hormone</category><category>GHRH</category><category>Ghrelin</category><category>Recovery</category><category>Explainer</category></item><item><title>The programmable body: how gene editing, cell therapy, and synthetic biology are changing what medicine can attempt</title><link>https://peptide.press/articles/the-programmable-body/</link><guid isPermaLink="true">https://peptide.press/articles/the-programmable-body/</guid><description>For most of its history, medicine has managed disease from the outside. A cluster of technologies now lets us edit, engineer, and reprogram biology directly — moving from treating symptoms toward rewriting the systems beneath them.</description><pubDate>Sun, 12 Jul 2026 00:00:00 GMT</pubDate><category>human-potential</category><category>Gene Editing</category><category>Cell Therapy</category><category>Synthetic Biology</category><category>Regenerative Medicine</category><category>Future Medicine</category></item><item><title>How to read a peptide Certificate of Analysis</title><link>https://peptide.press/articles/how-to-read-a-peptide-certificate-of-analysis/</link><guid isPermaLink="true">https://peptide.press/articles/how-to-read-a-peptide-certificate-of-analysis/</guid><description>Identity, purity, potency, net content — what each line on a COA actually proves, walked through on a real third-party report. A practical guide to reading testing documentation with confidence.</description><pubDate>Sat, 11 Jul 2026 00:00:00 GMT</pubDate><category>peptides</category><category>Testing</category><category>Analysis</category><category>COA</category><category>Quality Control</category></item><item><title>Why statistically significant does not always mean clinically important</title><link>https://peptide.press/articles/statistical-significance-clinical-importance/</link><guid isPermaLink="true">https://peptide.press/articles/statistical-significance-clinical-importance/</guid><description>A result can be statistically significant and still barely matter — or matter enormously and just miss significance. Learning to tell the difference is one of the most useful skills for reading research well.</description><pubDate>Sat, 11 Jul 2026 00:00:00 GMT</pubDate><category>research</category><category>Statistics</category><category>Clinical Research</category><category>Evidence</category><category>Study Design</category></item><item><title>GHK-Cu: a copper-binding peptide with a half-century of research behind it</title><link>https://peptide.press/articles/ghk-cu-wound-biology-to-skin/</link><guid isPermaLink="true">https://peptide.press/articles/ghk-cu-wound-biology-to-skin/</guid><description>A naturally occurring copper-binding peptide that researchers have studied for fifty years — and whose biology spans an unusually broad range of processes in skin and tissue repair.</description><pubDate>Fri, 10 Jul 2026 00:00:00 GMT</pubDate><category>peptides</category><category>GHK-Cu</category><category>Copper Peptides</category><category>Skin Biology</category><category>Research</category></item><item><title>MOTS-c and the mitochondrial signals behind exercise and metabolism</title><link>https://peptide.press/articles/mots-c-mitochondrial-signaling/</link><guid isPermaLink="true">https://peptide.press/articles/mots-c-mitochondrial-signaling/</guid><description>A tiny peptide encoded inside the mitochondria may help explain how our cells adapt to exercise and metabolic stress — and it is opening a fascinating window into the biology of aging.</description><pubDate>Thu, 09 Jul 2026 00:00:00 GMT</pubDate><category>longevity</category><category>MOTS-c</category><category>Mitochondria</category><category>Metabolism</category><category>Research</category></item><item><title>BPC-157: what decades of preclinical research have revealed — and what human studies have yet to answer</title><link>https://peptide.press/articles/bpc-157-limited-human-evidence/</link><guid isPermaLink="true">https://peptide.press/articles/bpc-157-limited-human-evidence/</guid><description>A peptide with an unusually broad preclinical literature and a remarkable breadth of healing signals across tissues — and a human research chapter that is just beginning.</description><pubDate>Wed, 08 Jul 2026 00:00:00 GMT</pubDate><category>peptides</category><category>BPC-157</category><category>Preclinical Research</category><category>Evidence Review</category></item><item><title>Understanding purity, potency, and net content: three measurements every peptide researcher should know</title><link>https://peptide.press/articles/why-a-99-percent-purity-result-can-mislead/</link><guid isPermaLink="true">https://peptide.press/articles/why-a-99-percent-purity-result-can-mislead/</guid><description>Three different numbers describe what is in a vial, and each answers a different question. Knowing what each one means makes you fluent in the language of a Certificate of Analysis.</description><pubDate>Wed, 08 Jul 2026 00:00:00 GMT</pubDate><category>peptides</category><category>Testing</category><category>Quality Control</category><category>Analysis</category></item><item><title>Tesamorelin: one of the rare peptides with extensive human clinical evidence</title><link>https://peptide.press/articles/tesamorelin-body-composition-trials/</link><guid isPermaLink="true">https://peptide.press/articles/tesamorelin-body-composition-trials/</guid><description>A growth-hormone-releasing peptide backed by large randomized trials and an FDA approval — a look at what a fully developed body of human peptide evidence can look like.</description><pubDate>Tue, 07 Jul 2026 00:00:00 GMT</pubDate><category>performance</category><category>Tesamorelin</category><category>Clinical Trials</category><category>Body Composition</category></item><item><title>Can biology be optimized? The emerging science of human potential</title><link>https://peptide.press/articles/can-biology-be-optimized/</link><guid isPermaLink="true">https://peptide.press/articles/can-biology-be-optimized/</guid><description>Biology is entering an era in which molecules, computation, and engineering are converging to answer questions that once belonged to science fiction. A look at where the real frontier is.</description><pubDate>Mon, 06 Jul 2026 00:00:00 GMT</pubDate><category>human-potential</category><category>Enhancement</category><category>Future Medicine</category><category>Analysis</category></item><item><title>From laboratory discovery to human trials: why translating peptide research takes time</title><link>https://peptide.press/articles/why-mouse-results-fail-to-translate/</link><guid isPermaLink="true">https://peptide.press/articles/why-mouse-results-fail-to-translate/</guid><description>The path from a promising finding in the lab to a proven human therapy is long by design. Understanding why makes you a sharper — and more patient — reader of early science.</description><pubDate>Sun, 05 Jul 2026 00:00:00 GMT</pubDate><category>research</category><category>Preclinical</category><category>Analysis</category><category>Translation</category></item><item><title>What the March 2026 FDA warning letters reveal about the limits of &quot;research use only&quot;</title><link>https://peptide.press/articles/march-2026-fda-peptide-warning-letters/</link><guid isPermaLink="true">https://peptide.press/articles/march-2026-fda-peptide-warning-letters/</guid><description>In a single day, the FDA told multiple peptide sellers that an RUO label does not control when the surrounding evidence establishes an intended human-drug use. The reasoning is worth reading closely.</description><pubDate>Thu, 02 Jul 2026 00:00:00 GMT</pubDate><category>research</category><category>Regulation</category><category>Enforcement</category><category>FDA</category><category>RUO</category></item><item><title>How to check a compound&apos;s clinical trial status yourself</title><link>https://peptide.press/articles/reading-clinicaltrials-gov-status/</link><guid isPermaLink="true">https://peptide.press/articles/reading-clinicaltrials-gov-status/</guid><description>ClinicalTrials.gov is public, free, and one of the fastest ways to see where a compound actually stands in human research. Here&apos;s how to read a record.</description><pubDate>Sun, 28 Jun 2026 00:00:00 GMT</pubDate><category>research</category><category>Clinical Trials</category><category>Explainer</category></item></channel></rss>